Nicolas Fritz
YOU?
Author Swipe
View article: ATP1A3 dysfunction causes motor hyperexcitability and afterhyperpolarization loss in a dystonia model
ATP1A3 dysfunction causes motor hyperexcitability and afterhyperpolarization loss in a dystonia model Open
Mutations in the gene encoding the alpha3 Na+/K+-ATPase isoform (ATP1A3) lead to movement disorders that manifest with dystonia, a common neurological symptom with many different origins, but for which the underlying molecular mechanisms r…
View article: Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains
Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains Open
Recent advances in immunotherapeutic approaches to the treatment of Alzheimer's disease (AD) have increased the importance of understanding the exact binding preference of each amyloid-beta (Aβ) antibody employed, since this determines bot…
View article: Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities
Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities Open
Therapeutic antibodies have been developed to target amyloid-beta (Aβ), and some of these slow the progression of Alzheimer’s disease (AD). However, they can also cause adverse events known as amyloid-related imaging abnormalities with ede…
View article: Table S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Table S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Proteomics data.
View article: Supplementary Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Supplementary Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Complete list of proteins.
View article: Figure S8 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S8 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Navtemadlin treatment does not affect tumor infiltrating lymphocytes.
View article: Figure S7 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S7 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Navtemadlin treatment does not affect tumor infiltrating myeloid cells.
View article: Figure S8 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S8 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Navtemadlin treatment does not affect tumor infiltrating lymphocytes.
View article: Figure S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Crispr deletion of p53 in clone 8.
View article: Figure S2 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S2 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Incucyte images.
View article: Figure S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Crispr deletion of p53 in clone 8.
View article: Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
The tumor suppressor protein p53 is mutated in close to 50% of human tumors and is dysregulated in many others, for instance by silencing or loss of p14ARF. Under steady-state conditions, the two E3 ligases MDM2/MDM4 interact wi…
View article: Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
The tumor suppressor protein p53 is mutated in close to 50% of human tumors and is dysregulated in many others, for instance by silencing or loss of p14ARF. Under steady-state conditions, the two E3 ligases MDM2/MDM4 interact wi…
View article: Figure S7 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S7 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Navtemadlin treatment does not affect tumor infiltrating myeloid cells.
View article: Figure S6 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S6 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Flow data radiation + Navtemadlin combination.
View article: Figure S5 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S5 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Images radiation + Navtemadlin combination.
View article: Figure S9 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S9 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Navtemadlin treatment does not lead to bone marrow suppression.
View article: Figure S2 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S2 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Incucyte images.
View article: Figure S9 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S9 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Navtemadlin treatment does not lead to bone marrow suppression.
View article: Table S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Table S1 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Proteomics data.
View article: Figure S4 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S4 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Navtemadlin treatment potentiates radiotherapy in p53+/+ B16-F10 melanoma cells.
View article: Figure S4 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S4 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Navtemadlin treatment potentiates radiotherapy in p53+/+ B16-F10 melanoma cells.
View article: Supplementary Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Supplementary Data from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Complete list of proteins.
View article: Figure S3 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S3 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
B16-F10 +/+ cells treated with increasing Navtemadlin concentrations over time.
View article: Figure S3 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S3 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
B16-F10 +/+ cells treated with increasing Navtemadlin concentrations over time.
View article: Figure S5 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S5 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Images radiation + Navtemadlin combination.
View article: Figure S6 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
Figure S6 from The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy Open
Flow data radiation + Navtemadlin combination.
View article: Table S6D from Membrane-Depolarizing Channel Blockers Induce Selective Glioma Cell Death by Impairing Nutrient Transport and Unfolded Protein/Amino Acid Responses
Table S6D from Membrane-Depolarizing Channel Blockers Induce Selective Glioma Cell Death by Impairing Nutrient Transport and Unfolded Protein/Amino Acid Responses Open
RNA sequencing data mibefradil vs control (DMSO)
View article: Supplementary Information from Membrane-Depolarizing Channel Blockers Induce Selective Glioma Cell Death by Impairing Nutrient Transport and Unfolded Protein/Amino Acid Responses
Supplementary Information from Membrane-Depolarizing Channel Blockers Induce Selective Glioma Cell Death by Impairing Nutrient Transport and Unfolded Protein/Amino Acid Responses Open
Supplementary Figure Legends and Materials and Methods
View article: Figure S3 from Membrane-Depolarizing Channel Blockers Induce Selective Glioma Cell Death by Impairing Nutrient Transport and Unfolded Protein/Amino Acid Responses
Figure S3 from Membrane-Depolarizing Channel Blockers Induce Selective Glioma Cell Death by Impairing Nutrient Transport and Unfolded Protein/Amino Acid Responses Open
Proteomics analysis